# Oncologic Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection for Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis.

**Autores:** Abdulla Hussain A, McGarry Jennifer, Kaczorowska Roza et al
**Revista:** Ann Surg Oncol (2026)
**PMID:** 41545613 | **PMCID:** —
**DOI:** [10.1245/s10434-025-19070-2](https://doi.org/10.1245/s10434-025-19070-2)
**Fuente:** PubMed (abstract only — full text vía DOI)

## Relevancia
Meta-análisis (varios estudios) sobre manejo axilar post-NAC. Foco en TAD (Targeted Axillary Dissection).

## Abstract
Increasing evidence supports the oncologic safety of de-escalating axillary surgery after neoadjuvant chemotherapy (NAC). For patients with node-positive (cN+) breast cancer initially whose axilla is downstaged after NAC (ycN0), sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) is acceptable, with controversy surrounding the optimal technique. This study aimed to assess the oncologic and survival outcomes of SLNB versus TAD for cN+ patients who are converted to ycN0 after NAC.

A systematic literature search of relevant databases was conducted. A meta-analysis using the Mantel-Haenszel method was performed to calculate odds ratios (ORs) of axillary recurrence (AR), 3-year disease-free survival (DFS), and overall survival (OS) for SLNB compared with TAD.

Five studies involving 2849 patients (SLNB, n = 1842; TAD, n = 1007) were included. The rate of AR did not differ between SLNB and TAD (OR, 1.23; 95% confidence interval [CI], 0.33-4.65; p = 0.76). Patients who underwent SLNB had a modestly reduced 3-year DFS (OR, 1.53; 95% CI, 1.11-2.12; p = 0.01) compared with those undergoing TAD. There was no difference in 3-year OS between SLNB and TAD (OR, 2.12; 95% CI, 0.59-7.55; p = 0.25).

Accurate axillary staging after NAC is important to guide adjuvant therapies. The rate of AR is very low and equivalent after SLNB or TAD for cN+ breast cancer patients who become ycN0 after NAC. Further studies are warranted to confirm whether TAD provides a clear survival advantage compared with SLNB in long-term follow-up evaluation.

## Acceso
Artículo no disponible en PMC. Acceder vía [DOI](https://doi.org/10.1245/s10434-025-19070-2) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1245/s10434-025-19070-2*
